**7. Conclusion**

In conclusion, MSCs represent a practical therapy in the search for a new treatment for SCI; this may be due to the fact that MSC therapy presents a large spectrum of favorable assets that make it particularly appealing. First, MSCs can be isolated from non-embryonic tissues (BM, adipose tissue, UC, and amniotic fluid, among others) via noninvasive techniques and are easily preserved and expanded in vitro*.* Furthermore, MSCs possess migratory properties that allow them to be administered through different routes and have minimal immunoreactivity towards the host, as well as a limited chance of developing a tumor. Numerous clinical trials have demonstrated their safety for transplantation in humans as well as their lack of any major side effects. However, an enormous improvement in motor recovery and sensory function is still missing, bringing out that additional investigation and new phase III clinical trials are needed in order to fully understand the mechanism of action of MSCs as well as the pathological mechanisms which prevent the restoration of neural circuits in SCI. Lastly, the use of combinatory strategies with specific drugs, biomaterials, or neurorehabilitation may be the key factor to translate their promising results into the clinical practice.
